Large-scale testing (Phase 3)Study completedNCT02566967
What this trial is testing
An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective
Who this might be right for
Rheumatoid Arthritis
Norman B. Gaylis, MD 20